Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07320872

Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.

It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease.

Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Psoriasis can present at any age. However, the disease onset appears to follow a bimodal distribution, peaking around 20-30 years of age and again around 50-60 years of age.

Psoriasis is a common skin disease characterized clinically by formation of erythematous and scaly plaques at different sites affecting mainly the extensor prominences, scalp, the lumbosacral area and the sites of trauma. It is a lifelong disease with spontaneous remissions and exacerbations.

The exact etiology is unknown, but it is considered to be an autoimmune disease mediated by T lymphocytes. It is considered the most prevalent T-cell-mediated inflammatory disease in human beings, in which, keratinocytes in focal skin regions are stimulated to proliferate with activation of the immune system mediated by primed T-lymphocytes.

There is an association of HLA antigens seen in many psoriatic patients, particularly in various racial and ethnic groups. Familial occurrence suggests its genetic predisposition .

The pathophysiology of psoriasis involves infiltration of the skin by activated T cells which stimulate the proliferation of keratinocytes. This dysregulation in keratinocyte turnover results in the formation of thick plaques. Other associated features include epidermal hyperplasia and parakeratosis. There are several treatment options available for mild psoriasis, including topical corticosteroids, vitamin D analogs, calcineurin inhibitors, keratolytics, and targeted phototherapy.

More severe disease might require systemic therapy, including phototherapy, acitretin, methotrexate, cyclosporine, or biologic therapy. Psoriasis is accompanied by comorbidities such as obesity, diabetes, and metaboloic syndrome. Although the pathogenesis is still unknown, systemic inflammation caused by adipokines released from visceral adipose tissue is thought to play a role .

Adipokines are various bioactive polypeptides produced and released by adipose tissue. Adipokines are thought to play an important role in the pathogenesis of obesity-related diseases such as insulin resistance, hypertension, inflammation, and metabolic disorders.

Vaspin (visceral adipose tissue-derived serine protease inhibitor also called Serpin A12), It belongs to the serpin group of proteins and is a serine protease inhibitor produced from visceral adipose tissue.Vaspin consists of 415 amino acids and weighing 47-kDa .

Vaspin is an adipokine with recently described anti-inflammatory properties. It has been reported to be expressed in various tissues, such as skin, liver, stomach and pancreas, in addition to adipose tissue in humans . The main source of vaspin in human skin was found to be keratinocytes. Vaspin in the skin is associated with the differentiation of keratinocytes and suppresses the expression of inflammatory mediators.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients.
  • Pateints with any age and gender.

Exclusion criteria

  • Pregnancy and lactation.
  • Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies.
  • Patients with associated inflammatory disease such as infections and autoimmune diseases.

Treatment and study plan

vaspin gene polymorphism

Biological

to detect the correlation between vaspin gene polymorphism and serum vaspin levels among psoriasis patients.

  • To detect the relationship between the risk of psoriasis and the vaspin gene polymorphism.
  • To detect correlation between vaspin gene polymorphism and the severity of psoriasis.

Other names: Serum Vaspin Levels

Primary outcomes

  1. Detection of vaspin gene polymorphism

    Time frame: 12 Months

    Assessment of vaspin gene polymorphism in psoriasis patients to determine the disease severity

Study contacts

Contact information is provided by the study sponsor or research team.

Mahmoud Ahmed Ali, Lecturer

CONTACT

[email protected]

+201002364902

Ola Mahmoud Samy Mohamed, MSC

CONTACT

[email protected]

+201025592922

Sponsors and collaborators

Lead sponsor

Aswan University

Other

Registry information

Official study title

Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris and Its Relation to Pathogenesis and Risk of the Disease

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 6, 2026
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.